Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Arcellx, Inc.

https://arcellx.com/

Latest From Arcellx, Inc.

Inside Gilead’s Community Oncology CAR-T Pilot

Scrip sat down with Kite Pharma EVP Cindy Perettie to talk about the program that Gilead is running with Tennessee Oncology to bring CAR-T therapy into the community setting.

CAR-T Cancer

Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies

CEO Daniel O’Day highlighted Gilead’s large pipeline and relative safety from patent expirations over the next few years in the company’s Q1 earnings call.

Sales & Earnings Companies

J&J/Legend Tout Carvykti In Earlier Lines As Competitors Move In

They have new data for the CAR-T after one to three lines of multiple myeloma treatment and Phase III patient-reported outcomes data, but Gilead and Gracell are nipping at the companies’ and BMS’s heels.

ImmunoOncology Cancer

BMS Forges Ahead With Next Round Of Multiple Myeloma Therapies

The drug maker provided updates at ASH on newer agents, including a GPRC5D-directed CAR-T therapy, a member of the CELMoD class and its entry into an increasingly crowded BCMA bispecific ring.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register